Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
|
|
NeuBase Therapeutics, Inc. (OHRP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/03/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits &nbs... |
| 07/31/2023 |
8-K
| Quarterly results |
| 06/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Form of Series A Common Stock Purchase Warrant",
"Form of Series B Common Stock Purchase Warrant",
"Form of Pre-Funded Common Stock Purchase Warrant (Registered Direct Offering)",
"Form of Pre-Funded Common Stock Purchase Warrant (PIPE Private Placement)",
"Form of Placement Agent Common Stock Purchase Warrant",
"Opinion of Paul Hastings LLP",
"Securities Purchase Agreement, (Registered Direct Offering)",
"Securities Purchase Agreement, (PIPE Private Placement)",
"Registration Rights Agreement",
"NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules" |
|
| 05/18/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
8-K
| Quarterly results |
| 12/29/2022 |
8-K
| Quarterly results |
| 12/21/2022 |
8-K
| Quarterly results |
| 10/24/2022 |
8-K
| Quarterly results |
| 10/14/2022 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 10/03/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 09/12/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/29/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/14/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/10/2022 |
8-K
| Quarterly results |
| 01/10/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Offer Letter of Employment, effective January 10, 2022, by and between NeuBase Therapeutics, Inc. and Todd Branning",
"NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 -- NeuBase Therapeutics, Inc. , a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Todd P. Branning as Chief Financial Officer . Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and investor relations for several publicly traded pharmaceutical companies. "Todd brings the highest level of sophistication in finance to NeuBase" said Dietrich A. Stephan, Ph.D., Founder, CEO and Chairman of NeuBase. “We are a truly unique genetic medicines platform company with a technol..." |
|
| 01/05/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors PITTSBURGH and CAMBRIDGE, Mass., Jan. 5, 2022 -- NeuBase Therapeutics, Inc . , a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Eric J. Ende, M.D., to the Company's Board of Directors. Dr. Ende has nearly 25 years of experience in advising biotechnology and life sciences companies to optimize corporate strategy and structure and maximize shareholder value. "Dr. Ende has the experience and perspective to recognize the opportunity ahead for NeuBase as it plans for the clinical development of its potentially transformational new class of precision genetic medicines," said Dietrich A. Stephan, P..." |
|
| 12/23/2021 |
8-K
| Quarterly results |
| 10/22/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/01/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/27/2021 |
8-K
| Quarterly results |
| 08/19/2021 |
8-K
| Quarterly results |
| 08/12/2021 |
8-K
| Quarterly results |
| 06/08/2021 |
8-K
| Quarterly results |
| 05/25/2021 |
8-K
| Quarterly results |
| 05/20/2021 |
8-K
| Quarterly results |
| 05/13/2021 |
8-K
| Quarterly results |
| 05/12/2021 |
8-K
| Quarterly results |
| 04/30/2021 |
8-K
| Quarterly results |
| 04/27/2021 |
8-K
| Quarterly results |
|
|
|